Literature DB >> 33671956

Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells.

Mio Yamaguchi1, Kiyoshi Takagi1, Koki Narita1, Yasuhiro Miki2, Yoshiaki Onodera3, Minoru Miyashita4, Hironobu Sasano3,5, Takashi Suzuki1.   

Abstract

Chemokines secreted from stromal cells have important roles for interactions with carcinoma cells and regulating tumor progression. C-C motif chemokine ligand (CCL) 5 is expressed in various types of stromal cells and associated with tumor progression, interacting with C-C chemokine receptor (CCR) 1, 3 and 5 expressed in tumor cells. However, the expression on CCL5 and its receptors have so far not been well-examined in human breast carcinoma tissues. We therefore immunolocalized CCL5, as well as CCR1, 3 and 5, in 111 human breast carcinoma tissues and correlated them with clinicopathological characteristics. Stromal CCL5 immunoreactivity was significantly correlated with the aggressive phenotype of breast carcinomas. Importantly, this tendency was observed especially in the CCR3-positive group. Furthermore, the risk of recurrence was significantly higher in the patients with breast carcinomas positive for CCL5 and CCR3 but negative for CCR1 and CCR5, as compared with other patients. In summary, the CCL5-CCR3 axis might contribute to a worse prognosis in breast cancer patients, and these findings will contribute to a better understanding of the significance of the CCL5/CCRs axis in breast carcinoma microenvironment.

Entities:  

Keywords:  breast carcinoma; chemokine; immunohistochemistry; prognosis; tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33671956      PMCID: PMC7919043          DOI: 10.3390/ijms22041918

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  37 in total

1.  CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer.

Authors:  Haixia Ding; Lianmei Zhao; Suli Dai; Lei Li; Fujun Wang; Baoen Shan
Journal:  Biomed Pharmacother       Date:  2015-12-29       Impact factor: 6.529

Review 2.  Chemokines and their receptors: drug targets in immunity and inflammation.

Authors:  Antonella Viola; Andrew D Luster
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  CC chemokine receptor-3 undergoes prolonged ligand-induced internalization.

Authors:  N Zimmermann; J J Conkright; M E Rothenberg
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

4.  Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.

Authors:  Mio Yamaguchi; Kiyoshi Takagi; Ai Sato; Yasuhiro Miki; Minoru Miyashita; Hironobu Sasano; Takashi Suzuki
Journal:  Breast Cancer       Date:  2020-04-20       Impact factor: 4.239

5.  CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation.

Authors:  Tomomitsu Miyagaki; Makoto Sugaya; Takashi Murakami; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Hitoshi Okochi; Kunihiko Tamaki; Shinichi Sato
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

6.  ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens.

Authors:  Kiyoshi Takagi; Yasuhiro Miki; Yoshiaki Onodera; Takanori Ishida; Mika Watanabe; Hironobu Sasano; Takashi Suzuki
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

Review 7.  The inflammatory chemokine CCL5 and cancer progression.

Authors:  Donatella Aldinucci; Alfonso Colombatti
Journal:  Mediators Inflamm       Date:  2014-01-02       Impact factor: 4.711

8.  Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment.

Authors:  Chiuan-Ren Yeh; Spencer Slavin; Jun Da; Iawen Hsu; Jie Luo; Guang-Qian Xiao; Jie Ding; Fu-Ju Chou; Shuyuan Yeh
Journal:  Mol Cancer       Date:  2016-01-20       Impact factor: 27.401

9.  Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.

Authors:  Vittoria D'Esposito; Domenico Liguoro; Maria Rosaria Ambrosio; Francesca Collina; Monica Cantile; Rosa Spinelli; Gregory Alexander Raciti; Claudia Miele; Rossella Valentino; Pietro Campiglia; Michelino De Laurentiis; Maurizio Di Bonito; Gerardo Botti; Renato Franco; Francesco Beguinot; Pietro Formisano
Journal:  Oncotarget       Date:  2016-04-26

Review 10.  Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.

Authors:  Yunus A Luqmani; Nada Alam-Eldin
Journal:  Med Princ Pract       Date:  2016-02-05       Impact factor: 1.927

View more
  5 in total

Review 1.  Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms.

Authors:  Mengsi Hu; Qianhui Wang; Bing Liu; Qiqi Ma; Tingwei Zhang; Tongtong Huang; Zhimei Lv; Rong Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-18

2.  Immunoregulation of Ghrelin in neurocognitive sequelae associated with COVID-19: an in silico investigation.

Authors:  Cristina Russo; Giovanna Morello; Giuliana Mannino; Antonella Russo; Lucia Malaguarnera
Journal:  Gene       Date:  2022-06-06       Impact factor: 3.913

3.  CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer.

Authors:  Yichun Tang; Yueyang Hu; Yuchun Niu; Lei Sun; Linlang Guo
Journal:  Front Med (Lausanne)       Date:  2022-02-17

4.  The Identification by Exome Sequencing of Candidate Genes in BRCA-Negative Tunisian Patients at a High Risk of Hereditary Breast/Ovarian Cancer.

Authors:  Dorra BenAyed-Guerfali; Chamseddine Kifagi; Wala BenKridis-Rejeb; Nihel Ammous-Boukhris; Wajdi Ayedi; Afef Khanfir; Jamel Daoud; Raja Mokdad-Gargouri
Journal:  Genes (Basel)       Date:  2022-07-22       Impact factor: 4.141

5.  Tumor Extracellular Vesicles Regulate Macrophage-Driven Metastasis through CCL5.

Authors:  Daniel C Rabe; Nykia D Walker; Felicia D Rustandy; Jessica Wallace; Jiyoung Lee; Shannon L Stott; Marsha Rich Rosner
Journal:  Cancers (Basel)       Date:  2021-07-10       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.